CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-03 | COLLIER EARL M JR Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2023-01-03 | Litvack Frank Director | Grant or award · Stock Option (Right to Buy) | +185,000 | 185,000 | ||
| 2023-01-03 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2023-01-03 | Krasney Karen EVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2023-01-03 | Krasney Karen EVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +11,878 | 11,878 | ||
| 2023-01-03 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2022-11-03 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | +18,932 | $1.39 | $26K | 20,047 |
| 2022-11-03 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise · Stock Option (Right to Buy) | −18,932 | 0 | ||
| 2022-07-06 | Avat Xavier CHIEF BUSINESS OFFICER | Purchase | +1,000 | $3.68 | $4K | 3,000 |
| 2022-06-30 | Musket David B Director | Option exercise | +10,796 | $1.39 | $15K | 23,543 |
| 2022-06-30 | Musket David B Director | Option exercise · Stock Option (Right to Buy) | −1,401 | 0 | ||
| 2022-06-30 | Musket David B Director | Option exercise · Stock Option (Right to Buy) | −4,750 | 0 | ||
| 2022-06-30 | Musket David B Director | Option exercise · Stock Option (Right to Buy) | −4,645 | 0 | ||
| 2022-06-29 | Avat Xavier CHIEF BUSINESS OFFICER | Purchase | +1,500 | $3.76 | $6K | 2,000 |
| 2022-06-29 | Musket David B Director | Sale | −28,215 | $3.77 | $106K | 12,747 |
| 2022-06-27 | Musket David B Director | Sale | −17,775 | $4.44 | $79K | 40,962 |
| 2022-05-23 | Avat Xavier CHIEF BUSINESS OFFICER | Grant or award · Stock Option (Right to Buy) | +370,000 | 370,000 | ||
| 2022-03-31 | Manzo Louis Director | Option exercise | +27,904 | $1.39 | $39K | 27,904 |
| 2022-03-31 | Manzo Louis Director | Shares withheld for taxes | −11,309 | $3.43 | $39K | 16,595 |
| 2022-03-31 | Manzo Louis Director | Option exercise · Stock Option (Right to Buy) | −15,455 | 0 |
Page 11 of 24 · 468 trades